Zenas BioPharma (ZBIO) Competitors

Zenas BioPharma logo
$23.91 -1.13 (-4.51%)
Closing price 03:58 PM Eastern
Extended Trading
$23.85 -0.06 (-0.25%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ZBIO vs. IMVT, ARWR, ORKA, KOD, and CGON

Should you buy Zenas BioPharma stock or one of its competitors? Zenas BioPharma's main competitors and comparable companies include Immunovant (IMVT), Arrowhead Pharmaceuticals (ARWR), Oruka Therapeutics (ORKA), Kodiak Sciences (KOD), and CG Oncology (CGON). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Zenas BioPharma compare to Immunovant?

Immunovant (NASDAQ:IMVT) and Zenas BioPharma (NASDAQ:ZBIO) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.

Immunovant has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -0.88, suggesting that its stock price is 188% less volatile than the broader market.

Zenas BioPharma has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunovantN/AN/A-$505.61M-$2.56N/A
Zenas BioPharma$10M169.82-$377.74M-$9.42N/A

In the previous week, Immunovant had 6 more articles in the media than Zenas BioPharma. MarketBeat recorded 10 mentions for Immunovant and 4 mentions for Zenas BioPharma. Immunovant's average media sentiment score of 0.63 beat Zenas BioPharma's score of 0.60 indicating that Immunovant is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Immunovant
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Zenas BioPharma
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

47.1% of Immunovant shares are owned by institutional investors. 1.9% of Immunovant shares are owned by insiders. Comparatively, 22.0% of Zenas BioPharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Immunovant's return on equity of -63.01% beat Zenas BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
ImmunovantN/A -63.01% -56.19%
Zenas BioPharma N/A -144.65%-59.83%

Immunovant currently has a consensus target price of $44.60, indicating a potential upside of 37.27%. Zenas BioPharma has a consensus target price of $46.71, indicating a potential upside of 86.56%. Given Zenas BioPharma's higher probable upside, analysts clearly believe Zenas BioPharma is more favorable than Immunovant.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immunovant
1 Sell rating(s)
3 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.62
Zenas BioPharma
1 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.56

Summary

Immunovant beats Zenas BioPharma on 9 of the 13 factors compared between the two stocks.

How does Zenas BioPharma compare to Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Zenas BioPharma (NASDAQ:ZBIO) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

Arrowhead Pharmaceuticals currently has a consensus price target of $98.71, indicating a potential upside of 126.15%. Zenas BioPharma has a consensus price target of $46.71, indicating a potential upside of 86.56%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Arrowhead Pharmaceuticals is more favorable than Zenas BioPharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arrowhead Pharmaceuticals
1 Sell rating(s)
3 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.73
Zenas BioPharma
1 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.56

Arrowhead Pharmaceuticals has a beta of 1.34, meaning that its share price is 34% more volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -0.88, meaning that its share price is 188% less volatile than the broader market.

Zenas BioPharma has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -160.64%. Zenas BioPharma's return on equity of -144.65% beat Arrowhead Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Arrowhead Pharmaceuticals-160.64% -172.62% -37.51%
Zenas BioPharma N/A -144.65%-59.83%

62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are owned by company insiders. Comparatively, 22.0% of Zenas BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Zenas BioPharma has lower revenue, but higher earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arrowhead Pharmaceuticals$450.82M13.69-$724.21M-$5.11N/A
Zenas BioPharma$10M169.82-$377.74M-$9.42N/A

In the previous week, Arrowhead Pharmaceuticals had 18 more articles in the media than Zenas BioPharma. MarketBeat recorded 22 mentions for Arrowhead Pharmaceuticals and 4 mentions for Zenas BioPharma. Zenas BioPharma's average media sentiment score of 0.60 beat Arrowhead Pharmaceuticals' score of -0.20 indicating that Zenas BioPharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Arrowhead Pharmaceuticals
2 Very Positive mention(s)
3 Positive mention(s)
9 Neutral mention(s)
4 Negative mention(s)
1 Very Negative mention(s)
Neutral
Zenas BioPharma
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Arrowhead Pharmaceuticals beats Zenas BioPharma on 10 of the 16 factors compared between the two stocks.

How does Zenas BioPharma compare to Oruka Therapeutics?

Zenas BioPharma (NASDAQ:ZBIO) and Oruka Therapeutics (NASDAQ:ORKA) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings.

Zenas BioPharma has a beta of -0.88, indicating that its share price is 188% less volatile than the broader market. Comparatively, Oruka Therapeutics has a beta of -0.34, indicating that its share price is 134% less volatile than the broader market.

Oruka Therapeutics' return on equity of -19.34% beat Zenas BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Zenas BioPharmaN/A -144.65% -59.83%
Oruka Therapeutics N/A -19.34%-18.74%

Oruka Therapeutics has lower revenue, but higher earnings than Zenas BioPharma. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zenas BioPharma$10M169.82-$377.74M-$9.42N/A
Oruka TherapeuticsN/AN/A-$105.43M-$2.11N/A

56.4% of Oruka Therapeutics shares are held by institutional investors. 22.0% of Zenas BioPharma shares are held by company insiders. Comparatively, 23.5% of Oruka Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Zenas BioPharma presently has a consensus target price of $46.71, indicating a potential upside of 86.56%. Oruka Therapeutics has a consensus target price of $141.00, indicating a potential upside of 44.51%. Given Zenas BioPharma's higher probable upside, research analysts clearly believe Zenas BioPharma is more favorable than Oruka Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zenas BioPharma
1 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.56
Oruka Therapeutics
1 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.82

In the previous week, Oruka Therapeutics had 11 more articles in the media than Zenas BioPharma. MarketBeat recorded 15 mentions for Oruka Therapeutics and 4 mentions for Zenas BioPharma. Zenas BioPharma's average media sentiment score of 0.60 beat Oruka Therapeutics' score of -0.02 indicating that Zenas BioPharma is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Zenas BioPharma
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Oruka Therapeutics
6 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Oruka Therapeutics beats Zenas BioPharma on 10 of the 13 factors compared between the two stocks.

How does Zenas BioPharma compare to Kodiak Sciences?

Kodiak Sciences (NASDAQ:KOD) and Zenas BioPharma (NASDAQ:ZBIO) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings.

Kodiak Sciences has a beta of 2.02, meaning that its stock price is 102% more volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -0.88, meaning that its stock price is 188% less volatile than the broader market.

Kodiak Sciences currently has a consensus target price of $117.86, indicating a potential upside of 20.24%. Zenas BioPharma has a consensus target price of $46.71, indicating a potential upside of 86.56%. Given Zenas BioPharma's higher probable upside, analysts clearly believe Zenas BioPharma is more favorable than Kodiak Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kodiak Sciences
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63
Zenas BioPharma
1 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.56

In the previous week, Kodiak Sciences had 11 more articles in the media than Zenas BioPharma. MarketBeat recorded 15 mentions for Kodiak Sciences and 4 mentions for Zenas BioPharma. Zenas BioPharma's average media sentiment score of 0.60 beat Kodiak Sciences' score of 0.21 indicating that Zenas BioPharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kodiak Sciences
2 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Zenas BioPharma
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Kodiak Sciences has higher earnings, but lower revenue than Zenas BioPharma. Kodiak Sciences is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kodiak SciencesN/AN/A-$229.97M-$4.08N/A
Zenas BioPharma$10M169.82-$377.74M-$9.42N/A

89.1% of Kodiak Sciences shares are owned by institutional investors. 44.4% of Kodiak Sciences shares are owned by insiders. Comparatively, 22.0% of Zenas BioPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Zenas BioPharma's return on equity of -144.65% beat Kodiak Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Kodiak SciencesN/A -287.64% -87.83%
Zenas BioPharma N/A -144.65%-59.83%

Summary

Kodiak Sciences beats Zenas BioPharma on 7 of the 12 factors compared between the two stocks.

How does Zenas BioPharma compare to CG Oncology?

CG Oncology (NASDAQ:CGON) and Zenas BioPharma (NASDAQ:ZBIO) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, media sentiment, risk, institutional ownership and earnings.

In the previous week, CG Oncology had 39 more articles in the media than Zenas BioPharma. MarketBeat recorded 43 mentions for CG Oncology and 4 mentions for Zenas BioPharma. CG Oncology's average media sentiment score of 0.70 beat Zenas BioPharma's score of 0.60 indicating that CG Oncology is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
CG Oncology
15 Very Positive mention(s)
7 Positive mention(s)
6 Neutral mention(s)
2 Negative mention(s)
2 Very Negative mention(s)
Positive
Zenas BioPharma
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

CG Oncology currently has a consensus price target of $102.22, suggesting a potential upside of 24.81%. Zenas BioPharma has a consensus price target of $46.71, suggesting a potential upside of 86.56%. Given Zenas BioPharma's higher possible upside, analysts plainly believe Zenas BioPharma is more favorable than CG Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CG Oncology
1 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.64
Zenas BioPharma
1 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.56

26.6% of CG Oncology shares are held by institutional investors. 4.8% of CG Oncology shares are held by insiders. Comparatively, 22.0% of Zenas BioPharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

CG Oncology has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -0.88, suggesting that its stock price is 188% less volatile than the broader market.

Zenas BioPharma has a net margin of 0.00% compared to CG Oncology's net margin of -3,851.09%. CG Oncology's return on equity of -24.58% beat Zenas BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
CG Oncology-3,851.09% -24.58% -23.40%
Zenas BioPharma N/A -144.65%-59.83%

CG Oncology has higher earnings, but lower revenue than Zenas BioPharma. CG Oncology is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CG Oncology$4.04M1,810.72-$160.99M-$2.76N/A
Zenas BioPharma$10M169.82-$377.74M-$9.42N/A

Summary

CG Oncology beats Zenas BioPharma on 11 of the 15 factors compared between the two stocks.

Get Zenas BioPharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for ZBIO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ZBIO vs. The Competition

MetricZenas BioPharmaBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.62B$3.92B$7.42B$10.86B
Dividend YieldN/A3.64%2.48%4.74%
P/E Ratio-2.5423.5332.4528.84
Price / Sales162.1615.598.085.38
Price / CashN/A22.6520.7221.66
Price / Book7.644.124.313.50
Net Income-$377.74M-$24.03M$3.51B$394.12M
7 Day Performance-14.64%-9.57%-7.89%-8.87%
1 Month Performance-15.15%-13.67%-10.43%-11.97%
1 Year Performance-31.37%-6.29%-2.77%-9.56%

Zenas BioPharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ZBIO
Zenas BioPharma
3.1715 of 5 stars
$23.91
-4.5%
$46.71
+95.4%
-32.6%$1.62B$10MN/A167
IMVT
Immunovant
2.2467 of 5 stars
$35.71
+1.6%
$44.60
+24.9%
+40.3%$7.26BN/AN/A315
ARWR
Arrowhead Pharmaceuticals
2.4585 of 5 stars
$49.00
-0.5%
$99.07
+102.2%
+12.0%$6.94B$829.45MN/A711
ORKA
Oruka Therapeutics
2.5414 of 5 stars
$109.50
+4.7%
$133.00
+21.5%
+245.3%$6.92BN/AN/A68
KOD
Kodiak Sciences
3.1216 of 5 stars
$108.06
+0.9%
$104.71
-3.1%
+401.9%$6.73BN/AN/A124

Related Companies and Tools


This page (NASDAQ:ZBIO) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners